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Rationale: Most patients who develop persistent airflow limitation do so either as a manifesta-
tion of chronic obstructive pulmonary disease that is largely related to smoking or as a conse-
quence of persistent asthma. We sought to compare the natural course of lung function
associated with persistent airflow limitation in subjects with and without asthma from early
to late adult life.
Methods: We studied 2552 participants aged 25 or more who had multiple questionnaire and
lung function data from the long-term prospective population-based Tucson Epidemiological
Study of Airway Obstructive Disease. Persistent airflow limitation was defined as FEV1/FVC
ratio consistently <70% in all completed surveys subsequent to the first survey with airflow lim-
itation. Participants were divided into nine groups based on the combination of their physician-
confirmed asthma status (never, onset 25 years, or onset >25 years) and the presence of
airflow limitation during the study follow-up (never, inconsistent, or persistent).
Results: Among subjects with an asthma onset 25 years, blood eosinophilia increased signif-
icantly the odds of developing persistent airflow limitation (adjusted ORs: 3.7, 1.4e9.5),
whereas cigarette smoking was the strongest risk factor for persistent airflow limitation among
non-asthmatics and among subjects with asthma onset after age 25 years. Among subjects with
persistent airflow limitation, the natural course of lung function differed between subjects
with asthma onset 25 years and non-asthmatics, with the former having lower FEV1 levels
at age 25 (predicted value for a 175-cm tall male of 3400 versus 4090 ml, respectively;grant award by the American Thoracic Society/Alpha1 Foundation, grants HL14136 and HL085195 by
stitute, grant 0660059Z by the American Heart Association, and an unrestricted grant from the Barry
his study was conducted with the support of the General Clinical Research Center of the University of
iratory Center, University of Arizona, 1501 N. Campbell Avenue, P.O. Box 245030, Tucson, AZ 85724-
: þ1 520 626 6970.
a.edu (S. Guerra).
ker B. Francis Fellowship.
8 Elsevier Ltd. All rights reserved.
1474 S. Guerra et al.p< 0.001) and the latter having greater FEV1 loss between age 25 and 75 (1590 versus 2140 ml;
pZ 0.003).
Conclusion: In subjects who have asthma onset before 25 years of age and persistent airflow
limitation in adult life, the bulk of the FEV1 deficit is already established before age 25 years.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Airflow limitation that is variable and reversible either
spontaneously or with treatment is a defining feature of
asthma.1,2 Yet, subgroups of patients with long-term persis-
tent asthma may develop irreversible airflow limitation,3e5
which has been associated with markers of disease severity5
and overall mortality risk.6 The possible progression of per-
sistent asthma into chronic airflow limitation is consistent
with observations showing that, at the population level,
co-existing diagnoses of asthma, chronic bronchitis and em-
physema are frequently reported by the same patient7,8
and that active asthma substantially increases the risk of
acquiring a subsequent diagnosis of chronic obstructive
pulmonary disease (COPD).9 Indeed, in the presence of irre-
versible airflow limitation, a differential diagnosis between
asthma and COPD can be quite difficult using the phy-
siologic tests that are routinely utilized in the clinical
setting.10e12
Understanding the natural course of lung function and the
patterns of risk factors for development of persistent airflow
limitation among asthmatics, as contrasted with those of
subjects with classical smoking-related COPD, is essential to
determine whether, how, and when prevention and treat-
ment strategies can be implemented to reduce the long-
term sequelae of this disease. However, population-based
long-term prospective studies on persistent airflow limita-
tion in subjects with asthma are scant. Seminal work by
Burrows and colleagues1 assessed the course and progno-
sis of chronic airway obstruction in 27 asthmatics who
already had moderate to severe airflow limitation at their
enrollment in the Tucson Epidemiological Study of Airway
Obstructive Disease (TESAOD). They found that subjects
with asthma had a slower FEV1 decline than did subjects
with smoking-related emphysema, but they did not study
how the natural course of lung function from young to late
adult life differed in these two groups. The large cohort of
the TESAOD study has now covered a sufficiently long period
with prospective follow-up of well-characterized respiratory
phenotypes and repeated lung function tests over a substan-
tial proportion of adult life for most of the participants, to
address this issue. The goal of the present study was to
determine risk factors and natural course of lung function
associated with persistent airflow limitation in subjects
with and without asthma in the TESAOD study.Methods
Study population
TESAOD is a population-based prospective cohort study
initiated in Tucson, AZ, in 1972. Details of the enrollmentprocess have been previously reported.13 During the follow-
up, new enrollees were added by marriages and births for
a final total of 5377 white participants.
TESAOD is composed of 13 surveys that took place
approximately every two years between 1972 and 1996.
All participants were eligible to take part in the first 12
surveys, whereas survey 13 was conducted on selected
subgroups based on previous reports of respiratory symp-
toms/disease or residence in Arizona. During each survey,
participants completed a standardized questionnaire and,
with the exception of survey 4, performed spirometric lung
function tests with a pneumotachygraph device, which was
calibrated daily, according to ATS guidelines.14 In survey 13,
spirometric tests were repeated 15 min after inhalation of
180 mg of albuterol via a pressured metered-dose inhaler
and a valved holding chamber.
For the present study, we used data from 2552 partic-
ipants who completed questionnaire and lung function tests
in at least two TESAOD surveys in which they were 25 years
or older. Only lung function data from surveys completed at
or after age 25 were used to minimize potential confound-
ing by individual variation in onset and length of the
plateau phase of lung function growth. Of the 2552
participants, 515 (20%) were 25 years or younger at the
time of enrollment into TESAOD, but they completed at
least two surveys in which they were 25 years or older
during the study follow-up.
Definitions and measurements
Participants were considered to have physician-confirmed
asthma if they reported to have ever had asthma and to
have been seen, diagnosed, or treated for asthma by
a doctor at any completed survey. Participants with asthma
were classified into two mutually exclusive groups based on
whether they had disease onset at/before age 25 years or
after age 25 years. We selected this age cut-off to be
consistent with the above mentioned age cut-off that was
chosen as initial point for analyses on lung function. Asthma
onset 25 years was defined as having asthma (as described
above) at any survey before age 25 or, for subjects enrolled
after age 25, as having asthma at enrollment into the study
and reporting being 25 years at first asthma attack or
having had ‘respiratory trouble’ before age 16.15 Asthma
onset >25 years was defined as either having no asthma
at enrollment and having new asthma at any subsequent
survey after age 25 or as having asthma at enrollment
into the study after age 25 and reporting age at first
asthma attack >25 years and no ‘respiratory trouble’
before age 16.
Airflow limitation was defined as FEV1/FVC ratio <70%.
Airflow limitation was defined as ‘‘persistent’’ if the subject
had FEV1/FVC values <70% in all completed lung function
Course of persistent airflow limitation 1475tests subsequent to the first survey with airflow limitation.
Otherwise, it was coded as ‘‘inconsistent’’. The categories
of no, inconsistent, and persistent airflow limitation were
created based on available observations. In lung function
analyses, missing observations were assumed to be at ran-
dom. Both subjects with prevalent airflow limitation and
subjects with incident airflow limitation were included in
this study to avoid selective removal of subjects with early
onset of airflow limitation. Because the FEV1/FVC ratio
declines significantly with aging, analyses on lung function
were also repeated after defining airflow limitation based
on lower limit of normal equations for FEV1/FVC.
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We categorized subjects as ever smokers if they had
smoked at least 1 packyear by the time they completed
their last survey.
A detailed description of assessment methods for skin
prick tests, IgE, eosinophil measurements, and other
clinical variables is included in Table E1 in the online
appendix.
Study design and statistical analyses
The 2552 study subjects were divided into nine mutually
exclusive groupsbasedon thecombinationof their physician-
confirmed asthma status (no asthma, asthma onset 25
years, or asthmaonset>25 years) and thepresenceof airflow
limitation during the study follow-up (never, inconsistent, or
persistent). The study design is summarized in Fig. 1.
Multinomial logistic regression was used to determine
factors associated with persistent and inconsistent airflow
limitation, as compared with no airflow limitation, in the
total population and separately for subjects with no
asthma, asthma onset 25 years, and asthma onset >25
years. Robust variance estimates were used to minimize the
effects of correlation within households. In order to
compare FEV1 trends over time across the groups withFigure 1 Summary of study design. The nine study groups were cr
status (no asthma, asthma onset 25 years, or asthma onset >25
follow-up (never, inconsistent, or persistent). *Only participants w
two surveys in which they were 25 years or older were eligible fopersistent airflow limitation while adjusting for the intra-
subject serial correlation of repeated observations and
reducing the impact of missing observations,17 we used
random coefficients models that included as fixed covari-
ates a categorical indicator of study groups, sex, height,
length of follow-up, age, age squared, an interaction
term between study groups and age, and an interaction
term between study groups and age squared. Because
FEV1 is part of the defining criteria of persistent airflow lim-
itation, FEV1 trends were compared using linear contrasts
only between pairs of groups with persistent airflow limita-
tion. In addition, the slope of FEV1 was computed for each
subject with at least three lung function tests 25 years of
age by regressing FEV1 against age. Two multivariate
logistic regression models were then used to determine fac-
tors associated with being in the fastest tertile and being in
the fastest quintile of FEV1 decline (i.e., having an FEV1
slope of at least 33 ml per year or at least 45 ml per year,
respectively). Statistical analyses were completed using
the statistical packages SPSS version 15.0 and Stata
version 9.0.
The study was approved by the Human Subjects Com-
mittee at the University of Arizona and all participants
provided informed consent.
Results
Of the 2552 subjects included in this study, 1778 (70%) had
no airflow limitation, 460 (18%) had inconsistent airflow
limitation, and 314 (12%) had persistent airflow limitation.
Fig. 2 shows the frequency of persistent and inconsistent
airflow limitation among subjects with no asthma, asthma
onset 25 years, and asthma onset >25 years. Subjects in
either asthma group were at increased risk of inconsistent
and persistent airflow limitation as compared with subjects
with no asthma. When analyses were stratified by smoking,eated based on the combination of physician-confirmed asthma
years) and the presence of airflow limitation during the study
ho completed questionnaire and lung function tests in at least
r the current study.
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Figure 2 Proportion of subjects with inconsistent and persistent airflow limitation in the groups with no asthma, asthma onset
25 years, and asthma onset >25 years. Data are presented for the total population as well as stratified by the groups of non-
smokers and smokers. P values refer to the comparison of proportion of any airflow limitation among subjects with no asthma,
asthma onset 25 years, and asthma onset >25 years.
1476 S. Guerra et al.the associations between asthma and airflow limitation
were significant both among nonsmokers and smokers.
Factors associated with airflow limitation
Table 1 shows the characteristics of the subjects in the nine
study groups (see methods). Factors potentially associated
with inconsistent and persistent airflow limitation were
tested in multinomial logistic regression models for the
total population and separately for subjects with no asthma,
asthma onset 25 years, and asthma onset >25 years
(Table 2). Male sex, age, packyears, elevated IgE, eosino-
philia, and asthma status were significantly associated
with persistent airflow limitation in the total population.
The risk for persistent airflow limitation was eight times
higher for subjects with asthma onset 25 years than sub-
jects with no asthma. The corresponding RR was lower
(4.9) but still highly significant for subjects with asthma
onset >25 years. Age and smoking were significantly asso-
ciated with persistent airflow limitation in all models strat-
ified by asthma status. However, the RRs for the association
between packyears and persistent airflow limitation were
substantially higher among subjects with no asthma or
asthma onset >25 years than among subjects with asthma
onset 25 years. In contrast, eosinophilia was associated
with an almost 4-fold increased risk of developing persis-
tent airflow limitation only among subjects with asthma
onset 25 years. Of note, in this group the RR for persi-
stent airflow limitation associated with eosinophilia was
particularly high among never smokers (6.8; 1.6e28.9).
Table E2 in the online data supplement shows multinomial
logistic regression models for inconsistent and persistent
airflow limitation separately for males and females. The
increased risk for persistent airflow limitation associated
with eosinophilia appeared stronger among females than
males, with the corresponding RRs being 2.1 (1.3e3.5)
and 1.5 (0.9e2.5), respectively. This trend was particu-
larly evident among subjects with asthma onset 25 years.
In this group, eosinophilia was associated with an RR
of 6.8 (1.6e28.4) among females and an RR of 1.9
(0.5e7.3) among males, although the interaction termbetween eosinophilia and sex was not significant (data not
shown).
Lung function
FEV1 levels during adult age were assessed in the study
groups based on lung function tests completed over age
25 (see Fig. E1 for distribution of available observations
by age). Fig. 3 shows that, inherent in the classification,
the groups with persistent airflow limitation had lower
FEV1 values as compared with controls, but the natural his-
tory of their lung function differed based on the presence
and time of onset of asthma. As compared with controls
with no asthma and no airflow limitation, subjects with
no asthma and persistent airflow limitation had only moder-
ate deficits of FEV1 at age 25 (mean deficit, 95% CI: 213,
16e410 ml), but they had 874 (665e1084) ml excess loss
of FEV1 between age 25 and 75. In contrast, subjects with
asthma onset 25 years and persistent airflow limitation
had larger deficits of FEV1 at age 25 (904, 637e1171 ml)
and a moderate excess loss of FEV1 between age 25 and
75 (322, 15e630 ml). Subjects with asthma onset >25 years
and persistent airflow limitation had a mean 524 (145e904)
ml deficit of FEV1 at age 25 and a 763 (372e1154) ml excess
loss of FEV1 between age 25 and 75. Linear contrasts indi-
cated that, as compared with subjects with no asthma
and persistent airflow limitation, subjects with asthma on-
set 25 years and persistent airflow limitation had signifi-
cantly lower FEV1 levels at age 25 (predicted values for
a 175-cm tall male: 4090 versus 3400 ml, respectively;
p< 0.001) and a significantly smaller FEV1 loss between
age 25 and 75 (2140 versus 1590 ml, respectively;
pZ 0.003). Predicted FEV1 values and FEV1 loss are shown
for each of the study groups in Fig. 3. In the online data sup-
plement, Fig. E2aed shows predicted FEV1 values from the
best-fitting random coefficients models stratified by sex
and smoking.
In order to estimate slopes of FEV1 decline for each of
the groups with persistent airflow limitation, random coef-
ficients models were re-run after excluding the age squared
term. The expected FEV1 decline in controls with no asthma
Table 1 Characteristics of the subjects in the nine study groups (N is 2552 unless otherwise specified)
No asthma (nZ 2109) Asthma onset Overall p value*
No airflow
limitation
Inconsistent
airflow
limitation
Persistent
airflow
limitation
25 years (nZ 193) >25 years (nZ 250)
No airflow
limitation
Inconsistent
airflow
limitation
Persistent
airflow
limitation
No
airflow
limitation
Inconsistent
airflow
limitation
Persistent
airflow
limitation
N 1552 360 197 99 45 49 127 55 68 N/A
Sex % (female) 57.9 55.3 34.5 53.5 62.2 46.9 73.2 58.2 47.1 <0.001
Age at first survey in years:
mean SD
45 18 58 15 59 15 35 14 43 14 48 16 43 17 56 14 60 13 <0.001
Number of completed lung function
tests over age 25 years: mean SD
5.4 3 7.2 3 5.9 3 5.4 3 7.4 3 6.4 3 5.3 3 6.9 3 5.7 3 <0.001
Years of follow-up on lung function
over age 25 years: mean SD
10.7 7 13.2 7 10.9 7 10.5 6 14.8 6 11.6 7 11.5 6 13.2 6 9.8 7 <0.001
Years of formal education (nZ 2512):
% with more than 12 years
55.0 39.9 33.8 69.1 54.5 58.3 59.7 41.8 23.5 <0.001
Chronic bronchitis (nZ 2550)
% Never 84.6 67.8 49.7 76.8 53.3 28.6 67.7 56.4 29.4 <0.001
% Sporadic 10.8 22.8 32.5 12.1 33.3 26.5 21.3 25.5 27.9
% Frequent 4.5 9.4 17.8 11.1 13.3 44.9 11.0 18.2 42.6
Dyspnea (MMRCa score 2) (nZ 2551)
% Never 78.1 64.4 50.8 63.6 46.7 34.7 52.8 45.5 16.2 <0.001
% Sporadic 13.8 22.2 21.8 22.2 35.6 22.4 22.8 27.3 22.1
% Frequent 8.1 13.3 27.4 14.1 17.8 42.9 24.4 27.3 61.8
Physician-confirmed emphysema
(nZ 2551) % ever
2.3 9.7 31.0 4.0 13.3 42.9 8.7 25.5 51.5 <0.001
Packyears at last completed survey
% <1 packyear 52.3 34.7 17.3 47.5 48.9 38.8 52.0 27.3 25.0 <0.001
% 1e19.9 packyears 18.7 15.3 8.1 27.3 8.9 12.2 25.2 20.0 11.8
% 20e49.9 packyears 21.6 28.6 26.9 22.2 24.4 26.5 17.3 38.2 22.1
% 50 packyears 7.5 21.4 47.7 3.0 17.8 22.4 5.5 14.5 41.2
Allergy skin tests (nZ 2390): % ever
positiveb
49.6 42.8 45.4 80.2 87.8 68.1 70.1 65.5 42.4 <0.001
Elevated IgE (nZ 2238): % everc 12.4 15.0 21.2 27.2 45.0 46.5 24.5 51.0 27.9 <0.001
Eosinophilia (nZ 2116): % everd 12.8 18.2 19.0 23.4 30.0 41.9 24.8 25.5 31.6 <0.001
*p value for the comparison across the nine groups.
a Modified Medical Research Council dyspnea scale.33
b Wheal at least 2 mm larger than the control wheal for at least one tested allergen in at least one of the three test surveys.
c IgE z score at least one standard deviation higher than the mean of the subject’s sex- and age-specific category in any of the measurements performed during the study.34 For example, this
would correspond to an IgE level >174 IU/ml for a woman between age 25 and 35 years.
d Eosinophils >4% or eosinophil z scores at least one standard deviation higher than the sex-specific mean in any of the measurements performed during the study. For example, this would
correspond to eosinophils >274 per mm3 for a woman.
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Table 2 Multinomial logistic regressions to predict inconsistent and persistent airflow limitation in the total population and s arately for subjects with no asthma, asthma onset
25 years, and asthma onset >25 years
Model 1: total
study population (nZ 2552)
(reference groupZ subjects with
no airflow limitation)
Model 2: no asthma (nZ 2109)
(reference groupZ subjects with
no asthma and no airflow limitation)
Model 3: asthma
onset 25 years (nZ 19
(reference groupZ subj ts with
asthma onset 25 years nd no
airflow limitation)
Model 4: Asthma
onset >25 years (nZ 250)
(reference groupZ subjects
with asthma onset >25 years
and no airflow limitation)
Inconsistent
airflow
limitation
RR (95% CI)
Persistent
airflow
limitation
RR (95% CI)
Inconsistent
airflow
limitation
RR (95% CI)
Persistent
airflow
limitation
RR (95% CI)
Inconsistent
airflow
limitation
RR (95% CI)
Persi ent
airflo
limit ion
RR (9 % CI)
Inconsistent
airflow
limitation
RR (95% CI)
Persistent
airflow
limitation
RR (95% CI)
Sex (male) 1.14 (0.90e1.45) 1.79 (1.34e2.38) 1.10 (0.84e1.43) 1.82 (1.29e2.58) 0.79 (0.31e2.02) 1.17 .50e2.72) 2.21 (1.00e4.88) 2.49 (1.17e5.26)
Age at first surveya 1.67 (1.55e1.81) 1.67 (1.52e1.84) 1.67 (1.53e1.82) 1.59 (1.42e1.78) 1.56 (1.17e2.09) 1.91 .43e2.55) 1.85 (1.45e2.35) 1.98 (1.54e2.54)
Packyearsb 1.20 (1.15e1.26) 1.34 (1.27e1.42) 1.20 (1.14e1.26) 1.35 (1.27e1.44) 1.23 (1.03e1.46) 1.22 .05e1.43) 1.28 (1.06e1.53) 1.43 (1.19e1.73)
Elevated IgEc 1.35 (0.99e1.82) 1.47 (1.02e2.12) 1.05 (0.72e1.53) 1.44 (0.90e2.32) 1.87 (0.77e4.56) 2.23 .92e5.41) 3.36 (1.52e7.46) 1.45 (0.61e3.45)
Eosinophiliad 1.25 (0.92e1.70) 1.74 (1.21e2.51) 1.29 (0.92e1.83) 1.36 (0.84e2.20) 1.72 (0.62e4.72) 3.66 .41e9.54) 1.01 (0.40e2.53) 2.16 (0.84e5.51)
Asthma
Onset 25 years
versus Never
3.64 (2.40e5.55) 8.10 (5.11e12.8) N/A N/A N/A N/A N/A N/A
Onset >25 years
versus Never
2.01 (1.40e2.88) 4.86 (3.36e7.03) N/A N/A N/A N/A N/A N/A
Sex, age, packyears, skin tests, IgE, eosinophilia, and asthma status (in Model 1) were tested as independent variables; all models were lso adjusted for the duration of follow-up; factors that
were significant in Model 1 were retained in all models.
a RR associated with 10-year increase.
b RR associated with 10-packyear increase.
c IgE z score at least 1 SD higher than the mean of the subject’s sex- and age-specific category in any of the measurements perfor ed during the study.34
d Eosinophils >4% or eosinophil z scores at least one SD higher than the sex-specific mean in any of the measurements performed d ring the study.ep
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Figure 3 Levels and decline of FEV1 during adult age for the
study groups of subjects with no asthma and persistent airflow
limitation (black line; number of subjectsZ 197; number of ob-
servationsZ 1159), subjects with asthma onset 25 years and
persistent airflow limitation (red line; number of subjectsZ 49;
number of observationsZ 313), and subjects with asthma onset
>25 years and persistent airflow limitation (gold line; number of
subjectsZ 68; number of observationsZ 385). Predicted
values for subjects with no asthma and no airflow limitation
(green line; number of subjectsZ 1552; number of observa-
tionsZ 8433) are also reported for comparison. Depicted values
represent predicted values for a 175-cm tall male from the best-
fitting random coefficients model.1
Course of persistent airflow limitation 1479and no airflow limitation was 26 ml per year. Subjects with
no asthma and persistent airflow limitation had a signifi-
cantly faster FEV1 decline than did subjects with asthma
onset 25 years and persistent airflow limitation or sub-
jects with asthma onset >25 years and persistent airflow
limitation (43 [95% CI: 40e46] ml per year, 30 [24e36] ml
per year, and 35 [29e40] ml per year, respectively).
We used multivariate logistic regression models to iden-
tify factors associatedwith being in the fastest tertile of FEV1
decline (i.e., having an FEV1 slope of at least 33 ml per year).
Only male sex and packyears, but not IgE levels or eosino-
philia, were associated with increased odds of being in the
fastest tertile of FEV1 decline (adjusted ORs: 1.98, 1.63e
2.41, for male sex; and 1.09, 1.05e1.13, for a 10-packyears
increase). Similarly, male sex and packyears were the only
significant risk factors for being in the fastest quintile of
FEV1 decline (i.e., having an FEV1 slope of at least 45 ml1 Statistical comparisons were conducted only between pairs of groups
below
Subjects with no
asthma/no airflow
limitation
Subjec
asthm
airflow
Predicted FEV1 values (95% CI) in
liters at age 25
4.31 (4.26e4.35) 4.09 (3
Predicted FEV1 loss (95% CI) in
liters between age 25 and 75
1.26 (1.21e1.32) 2.14 (1
*Significantly lower than subjects with no asthma/persistent airflow l
**Significantly lower than subjects with no asthma/persistent airflow
asthma onset >25 years/persistent airflow limitation (pZ .08).per year), with the corresponding adjusted ORs being 2.24,
1.77e2.84; and 1.10, 1.05e1.15, respectively.
Sensitivity analyses
To evaluate potential loss-to-follow-up bias, analyses were
repeated and results confirmed after selecting for the
1149 subjects who had 6 lung function tests (Fig. E3)
and after removing observations from survey 13, in which
only subgroups of participants were eligible to participate
(Fig. E4). Results were also unchanged when persistent air-
flow limitation was defined as FEV1/FVC ratio consistently
<70% plus FEV1 % predicted <80% during or after the first
survey with FEV1/FVC< 70% (Fig. E5). Random coefficients
models including only observations over age 40 years re-
turned very similar trends across the study groups (Fig. E6).
Because the ratio FEV1/FVC declines significantly with
aging in the general population, random coefficients
models for lung function were also repeated after defining
the study groups based on airflow limitation as assessed
by an FEV1/FVC ratio below the lower limit of normal
16
(Fig. E7). The main differences in the natural course of
lung function associated with persistent airflow limitation
between subjects with asthma onset 25 years and non-
asthmatics were confirmed, with the former having lower
FEV1 levels at age 25 and the latter having greater FEV1
loss between age 25 and 75. In these models, the natural
course of lung function of subjects with persistent airflow
limitation was similar between the groups with asthma on-
set 25 years and asthma onset >25 years.
Finally, using data from a subgroup of 418 adult subjects
who completed pulmonary function tests before and after
albuterol in survey 13, we found that 70% (23/33) of subjects
with persistent airflow limitation had GOLD-defined COPD
(FEV1/FVC< 70% after bronchodilator) in survey 13. This pro-
portion was 60% (9/15) and 78% (14/18) among subjects with
and without asthma, respectively.
Discussion
Using a population-based long-term prospective cohort,
we identified subjects who had persistent airflow limita-
tion during the study and compared risk factors and
natural course of their disease based on the presence and
age at onset of asthma. Findings of this study provide
novel evidence that (1) subjects with asthma account for
a significant proportion of persistent airflow limitation inwith persistent airflow limitation (see methods) and are reported
ts with no
a/persistent
limitation
Subjects with asthma
onset 25 years/
persistent airflow
limitation
Subjects with
asthma onset
>25 years/persistent
airflow limitation
.90e4.29) 3.40 (3.14e3.67)* 3.78 (3.40e4.16)
.94e2.34) 1.59 (1.29e1.89)** 2.03 (1.64e2.42)
imitation (p< .001).
limitation (pZ .003) and borderline lower than subjects with
1480 S. Guerra et al.the general population; (2) the profile of risk factors for
developing persistent airflow limitation is dependent
upon the presence and the age at onset of asthma,
with blood eosinophilia being the strongest risk factor
among subjects with asthma onset before age 25 years;
(3) among patients who have asthma before age 25,
development of persistent airflow limitation in adult age
is mainly associated with deficits that are already
established by the time these subjects reach the growth
plateau of their lung function.
Factors associated with persistent airflow
limitation
Consistent with the well-known inverse relationship be-
tween the ratio FEV1/FVC and age,
18,19 aging was strongly
associated with airflow limitation both among subjects
with and without asthma. However, lifetime exposure to
cigarette smoking was associated with an increased risk
for persistent airflow limitation that was almost twice as
high among subjects with no asthma or asthma onset >25
years than among subjects with asthma onset 25 years.
In contrast, among subjects with asthma onset 25 years,
eosinophilia was the strongest risk factor for persistent air-
flow limitation. Eosinophilia is a known risk factor for the
development of respiratory symptoms20,21 and, among asth-
matics, is associated with lung function impairment22,23
and mortality risk.24,25 In a cross-sectional study of 132 non-
smoking outpatients with severe asthma, sputum eosino-
phils 2% were associated with an almost 8-fold increase
in the odds of having postbronchodilator FEV1 or FEV1/
FVC< 75% predicted.22 Similarly, among children with
asthma in the Childhood Asthma Management Program co-
hort levels of sputum and circulating eosinophils were
higher in subjects with at least 1% per year loss in FEV1 %
predicted than in subjects with non-significant FEV1
loss.23 However, the present study is the first population-
based study showing that eosinophilia predicts develop-
ment of persistent airflow limitation among adults who
had asthma onset in their first 25 years of life. Our findings
support a major role for eosinophilia in the smoking-inde-
pendent component of the phenotypic overlap between
asthma and COPD, as suggested by the particularly strong
association between eosinophilia and persistent airflow lim-
itation among non-smoker asthmatics.
Natural history of lung function
Because FEV1 represents the numerator of the ratio ‘FEV1/
FVC’, levels of FEV1 are expected to be reduced in most pa-
tients with airflow limitation. However, in adults these FEV1
deficits can be the result of any combination between
lower FEV1 levels at the beginning of adult age or an accel-
erated FEV1 decline during adulthood.
26 One of the major
findings of our study is that, among subjects who had
asthma onset 25 years, persistent airflow limitation in
adult age was strongly associated with FEV1 deficits that
were already established by young adulthood. Whether
these deficits are related to early airway remodeling or
impaired lung development, or both, remains to be deter-
mined. These findings are consistent with those of severalother prospective studies e including the Dunedin Multidis-
ciplinary Health and Development Study,18 the Melbourne
Asthma Study,27 and the British 1958 Birth Cohort28 e in
which persistent childhood asthma was associated with
lung function deficits that are present before adult life be-
gins and track over time from childhood to mid-adult life. In
the European Community Respiratory Health Survey, per-
cent predicted FEV1 values at age 20e44 years were strong
predictors of asthma severity and persistence during the
follow-up period.29 In addition, in the birth cohort of the
Children’s Respiratory Study our group has previously found
that children who start life with low levels of lung function
have lower expiratory flows throughout childhood30 as well
as lower FEV1/FVC levels at age 22
31 as compared with their
peers, suggesting that early exposures and/or genetic fac-
tors also play a role in determining levels of lung function
that will be attained before entering adult life. In our
study, the impact of asthma on early deficits of lung func-
tion appeared stronger among males (Fig. E2a), who are
known to be at increased risk for severe and/or persistent
childhood asthma as compared with females, and among
nonsmokers (Fig. E2c).
Conversely, subjects with no asthma developed persis-
tent airflow limitation mainly in response to cigarette
smoking and, thus, they showed only mild FEV1 deficits at
age 25 but steeper FEV1 decline over adult life. The natural
course of lung function of subjects who had asthma onset
after age 25 years included both moderate FEV1 deficits
in young adulthood and accelerated FEV1 decline thereaf-
ter, although these results should be interpreted with cau-
tion because of the possibility of reverse causality (i.e.,
acquiring a diagnosis of adult-onset asthma might be the
consequence rather than the cause of the steep decline
of lung function) and the small number of observations be-
fore age 40 in this group.
The different natural history of lung function between
subjects who developed persistent airflow limitation with
or without asthma is consistent with the observation that
eosinophilia, the strongest risk factor for persistent airflow
limitation among subjects with asthma onset 25 years,
was not associated with FEV1 decline. This observation sug-
gests that eosinophilia influences lung function among sub-
jects with childhood asthma mainly by affecting FEV1 levels
that are attained before young adult age.
Within our study design, we were unable to study
potential effects of anti-inflammatory treatments32 on
asthma progression. In addition, the small sample size of
some of our study groups suggests the importance of other
studies to replicate these findings. As with most large
epidemiological studies, postbronchodilator lung function
tests were not available for the vast majority of TESAOD
participants. Thus, to what extent persistent airflow limita-
tion can be used as a surrogate of GOLD-defined COPD is not
known, although sensitivity analyses from a subgroup of 418
TESAOD participants suggested acceptable correlations be-
tween these two phenotypes. We also acknowledge that,
although a maximum 24-year follow-up was possible in TE-
SAOD, subjects enrolled in this study were followed on av-
erage for 11 years. Thus, we studied the natural course of
the disease over adult life by combining information from
multiple sub-cohorts of subjects who differed in age at
enrollment into the study and length of follow-up.
Course of persistent airflow limitation 1481However, this is an unavoidable limitation of most large
prospective studies in adults. The relatively homogeneous
distribution of available observations over the entire span
of adult life (Fig. E1) and the use of statistical techniques
that are specifically designed for analysis of unbalanced
longitudinal data17 should have minimized the impact of
this limitation in our study.
Conclusions
In summary, development of persistent airflow limitation in
adult patients with asthma is a common event and accounts
for a significant proportion of the public health burden of
obstructive lung disease. We showed that blood eosino-
philia is the strongest risk factor for the development of
persistent airflow limitation among patients with asthma
onset 25 years and that, among these patients, the bulk of
lung function impairment is already established by young
adulthood. Therefore, future prevention programs will
need to identify and target these patients before they
enter adult life.
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